nach oben

Die Pathologie

Erschienen in:

05.07.2016 | Gynäkologische Tumoren | Schwerpunkt: Grading-Systeme

Grading gynäkologischer Tumoren

Aktuelle Aspekte

verfasst von: Prof. Dr. L.-C. Horn, D. Mayr, C. E. Brambs, J. Einenkel, I. Sändig, K. Schierle

Erschienen in: Die Pathologie | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Grading bei Tumoren des weiblichen Genitaltrakts hat eine sehr unterschiedliche Bedeutung. Für Plattenepithel- und Adenokarzinome der Vulva, Vagina und der Cervix uteri gibt es kein verbindliches Gradingsystem. Bei den endometrioiden Endometriumkarzinomen (Typ-1-Karzinomen) ist das Grading therapeutisch und prognostisch relevant. Das von der FIGO vorgeschlagene 3‑stufige Grading in Abhängigkeit vom Prozentsatz des soliden Tumoranteils hat nach wie vor seine Gültigkeit. Bei den neuroendokrinen Tumoren des Uterus erfolgt ein Grading in Analogie zu den gastrointestinalen Tumoren. Bei Leiomyosarkomen wird kein Grading durchgeführt. Bei den endometrialen Stromasarkomen werden in Abhängigkeit von der Morphologie, der Immunhistologie, ergänzt durch die Molekularpathologie Low- und High-grade-Tumoren unterschieden. Unter Berücksichtigung der Tubulusformation der Sertoli-Zellen und der Menge intratumoralen primitiven gonadalen Stromas erfolgt das Grading bei Sertoli-Leydig-Zell-Tumoren des Ovars und beim unreifen Teratom in Abhängigkeit von der Ausdehnung primitiver Neurotubuli. Für endometrioide, seromuzinöse und muzinöse Ovarialkarzinome wird das FIGO-Grading für endometrioide Endometriumkarzinome empfohlen. Für chemotherapierte seröse High-grade-Karzinome wurde ein Regressionsgrading etabliert. Molekularbiologische Daten spielen derzeit bei gynäkologischen Tumoren für das Grading (noch) keine Rolle.

Abiko K, Mandai M, Hamanishi J, Matsumura N, Baba T, Horiuchi A, Mikami Y, Yoshioka S, Wakasa T, Shiozawa T, Konishi I (2010) Oct4 expression in immature teratoma of the ovary: relevance to histologic grade and degree of differentiation. Am J Surg Pathol 34(12):1842–1848PubMedCrossRef

Acs G, Pasha T, Zhang PJ (2004) WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 23(2):110–118PubMedCrossRef

Ali RH, Seidman JD, Luk M, Kalloger S, Gilks CB (2012) Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor. Int J Gynecol Pathol 31(6):499–506PubMedCrossRef

Alkushi A, Abdul-Rahman ZH, Lim P, Schulzer M, Coldman A, Kalloger SE, Miller D, Gilks CB (2005) Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol 29(3):295–304PubMedCrossRef

Aragona AM, Cuneo NA, Soderini AH, Alcoba EB (2014) An analysis of reported independent prognostic factors for survival in squamous cell carcinoma of the vulva: Is tumor size significance being underrated? Gynecol Oncol 132(3):643–648PubMedCrossRef

Artioli G, Wabersich J, Ludwig K, Gardiman MP, Borgato L, Garbin F (2015) Rare uterine cancer: carcinosarcomas. Review from histology to treatment. Crit Rev Oncol Hematol 94(1):98–104PubMedCrossRef

Atienza-Amores M, Guerini-Rocco E, Soslow RA, Park KJ, Weigelt B (2014) Small cell carcinoma of the gynecologic tract: a multifaceted spectrum of lesions. Gynecol Oncol 134(2):410–418PubMedCrossRef

AWMF (2014) S3-Leitlinie Diagnostik,Therapie und Nachsorge derPatientin mit Zervixkarzinom. AWMF-Leitliniennummer 032/033OL. http://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Zervixkarzinom_2014-10.pdf. Zugegriffen: 01. April 2016

AWMF (2015) S2k-Leitlinie zur Diagnostik, Therapie und Nachsorge des Vulvakarzinoms und seiner Vorstufen. AWMF-Leitliniennummer 015/059. http://www.awmf.org/uploads/tx_szleitlinien/015-059l_S2k_Vulvakarzinom_und_Vorstufen_Diagnostik_Therapie_2016-03_1.pdf. Zugegriffen: 01. April 2016

10.

Ayhan A, Taskiran C, Yuce K, Kucukali T (2003) The prognostic value of nuclear grading and the revised FIGO grading of endometrial adenocarcinoma. Int J Gynecol Pathol 22(1):71–74PubMedCrossRef

11.

Baergen RN, Rutgers JL (1994) Mural nodules in common epithelial tumors of the ovary. Int J Gynecol Pathol 13(1):62–72PubMedCrossRef

12.

Baker PM, Oliva E (2015) Prognostic factors in uterine cancer. In: Muggia F, Oliva E (Hrsg) Uterine cancer. Screening, diagnosis, and treatment. Springer, Berlin, Heidelberg, New York, S 105–141

13.

Bell D, Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609–615CrossRef

14.

Bernardini MQ, Gien LT, Lau S, Altman AD, Gilks B, Ferguson SE, Köbel M, Samouëlian V, Wesa M, Cameron A, Nelson G, Han G, Clarke B, Ho TC, Panzarella T, Atenafu EG, McAlpine JN (2016) Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecol Oncol 141(1):148–154PubMedCrossRef

15.

Bhat RA, Lim YK, Chia YN, Yam KL (2013) Sertoli-Leydig cell tumor of the ovary: analysis of a single institution database. J Obstet Gynaecol Res 39(1):305–310PubMedCrossRef

16.

Blecharz P, Karolewski K, Bieda T, Klimek M, Pudelek J, Kojs E, Zur K, Dzialak P, Urbanski K (2008) Prognostic factors in patients with carcinoma of the vulva – our own experience and literature review. Eur J Gynaecol Oncol 29(3):260–263PubMed

17.

Blecharz P, Reinfuss M, Ryś J, Jakubowicz J, Skotnicki P, Wysocki W (2013) Radiotherapy for carcinoma of the vagina. Immunocytochemical and cytofluorometric analysis of prognostic factors. Strahlenther Onkol 189(5):394–400PubMedCrossRef

18.

Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM (2012) Reclassification of serous ovarian carcinoma by a 2‑tier system: a Gynecologic Oncology Group Study. Cancer 118(12):3087–3094PubMedCrossRef

19.

Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N (2015) Chemotherapy response score: Development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol 33(22):2457–2463PubMedCrossRef

20.

Broders AC (1926) Carcinoma grading and practical application. Arch Pathol 2:376–381

21.

Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67–73CrossRef

22.

Clarke BA, Gilks CB (2010) Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol 63(5):410–415PubMedCrossRef

23.

Coindre JM (2013) Grading and staging of sarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (Hrsg) WHO classification of tumours of soft tissue and bone. IARC, Lyon, S 17–18

24.

Coindre JM (2006) Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med 130(10):1448–1453PubMed

25.

Colgan TJ, Hirschowitz L, Kim I, McCluggage WG (2014) Neuroendocrine tumours of the uterine cervix. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reporductive tract. IARC, Lyon, S 196–198

26.

Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C, ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group (2016) ESMO-ESGO-ESTRO Consensus Conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol 27(1):16–41PubMedCrossRef

27.

Crum CP, Herrington CS, McCluggage WG, Regauer S, Wilkinson EJ (2014) Epithelial tumours of the vulva. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reporductive tract. IARC, Lyon, S 232–241

28.

Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F (1990) Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 38(3):352–357PubMedCrossRef

29.

Denschlag D, Thiel FC, Ackermann S, Harter P, Juhasz-Boess I, Mallmann P, Strauss HG, Ulrich U, Horn LC, Schmidt D, Vordermark D, Vogl T, Reichardt P, Gaß P, Gebhardt M, Beckmann MW (2015) Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). Geburtshilfe Frauenheilkd 75(10):1028–1042PubMedPubMedCentralCrossRef

30.

Deodhar KK, Suryawanshi P, Shah M, Rekhi B, Chinoy RF (2011) mmature teratoma of the ovary: a clinicopathological study of 28 cases. Indian J Pathol Microbiol 54(4):730–735PubMed

31.

Diaz De Vivar A, Roma AA, Park KJ, Alvarado-Cabrero I, Rasty G, Chanona-Vilchis JG, Mikami Y, Hong SR, Arville B, Teramoto N, Ali-Fehmi R, Rutgers JK, Tabassum F, Barbuto D, Aguilera-Barrantes I, Shaye-Brown A, Daya D, Silva EG (2013) Invasive endocervical adenocarcinoma: proposal for a new pattern-based classification system with significant clinical implications: a multi-institutional study. Int J Gynecol Pathol 32(6):592–601PubMedCrossRef

32.

Diaz-Padilla I, Malpica AL, Minig L, Chiva LM, Gershenson DM, Gonzalez-Martin A (2012) Ovarian low-grade serous carcinoma: a comprehensive update. Gynecol Oncol 126(2):279–285PubMedCrossRef

33.

Eggen T, Arnes M, Moe B, Straume B, Orbo A (2007) Prognosis of early cervical cancer (FIGO Stages IA2, IB, and IIA) in northern Norway predicted by malignancy grading score and objective morphometric image analysis. Int J Gynecol Pathol 26(4):447–456PubMedCrossRef

34.

Ellenson LH, Carinelli SG, Cho KR, Kim KR, Kupryjanczyk, Prat J, Singer G (2014) Endometrioid ovarian tumour. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reporductive tract. IARC, Lyon, S 29–32

35.

Ferenczy AS, Colgan TJ, Herrington CS, Hirschowitz L, Loening T, Park KJ, Stoler M, Wells M, Wilbur DC, Wright T (2014) Epithelial tumours of the vagina. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reporductive tract. IARC, Lyon, S 10–17

36.

Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA (2007) Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 31(11):1653–1661PubMedCrossRef

37.

Friedlander ML, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, Selle F, Small W, Witteveen E, Russell P (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract. Int J Gynecol Cancer 24(9 Suppl 3):S78–S82PubMedCrossRef

38.

Garg K, Soslow RA (2012) Strategies for distinguishing low-grade endometrioid and serous carcinomas of endometrium. Adv Anat Pathol 19(1):1–10PubMedCrossRef

39.

Gilks CB (2004) Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 23:200–205PubMedCrossRef

40.

Gilks CB, Prat J (2009) Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 40(9):1213–1223PubMedCrossRef

41.

Göbel U, Calaminus G, Schneider DT, Koch S, Teske C, Harms D (2006) The malignant potential of teratomas in infancy and childhood: the MAKEI experiences in non-testicular teratoma and implications for a new protocol. Klin Padiatr 218(6):309–314PubMedCrossRef

42.

Gonzales-Crussi F (1982) Extragonadal teratomas. Atlas of tumour pathology. 2nd Series, fasc. 18. Armed Forces Institute of Pathology, Washington DC

43.

Groen RS, Gershenson DM, Fader AN (2015) Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all. Gynecol Oncol 136(2):373–383PubMedCrossRef

44.

Gungorduk K, Ozdemir A, Ertas IE, Selcuk I, Solmaz U, Ozgu E, Mat E, Gokcu M, Karadeniz T, Akbay S, Sanci M, Meydanli MM, Ayaz D, Gungor T (2015) Is mucinous adenocarcinoma of the endometrium a risk factor for lymph node involvement? A multicenter case-control study. Int J Clin Oncol 20(4):782–789PubMedCrossRef

45.

Guseh SH, Rauh-Hain JA, Tambouret RH, Davis M, Clark RM, Boruta DM, Goodman A, Growdon WB, Schorge JO, del Carmen MG (2014) Transitional cell carcinoma of the ovary: a case-control study. Gynecol Oncol 132(3):649–653PubMedCrossRef

46.

Hart WR (2005) Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 24(1):4–25PubMed

47.

Hauptmann S, du Bois A, Meinhold-Herlein I, Pfisterer J, Avril S (2014) Histological grading of epithelial ovarian cancer. Review and recommendation. Pathologe 35(5):497–503PubMedCrossRef

48.

Höhn AK, Einenkel J, Wittekind C, Horn LC (2014) New FIGO classification of ovarian, fallopian tube and primary peritoneal cancer. Pathologe 35(4):322–326PubMedCrossRef

49.

Horn LC, Beckmann MW, Follmann M, Koch MC, Mallmann P, Marnitz S, Schmidt D (2015) S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology. Pathologe 36(6):585–593PubMedCrossRef

50.

Horn LC, Bilek K, Fischer U, Hentschel B (2016) Prognostic impact of conventional tumor grade in surgically treated FIGI stage IB to IIB squamous cell cancer. Int J Gynecol Cancer 25(Suppl 2):823–824

51.

Horn LC, Dallacker M, Bilek K (2009) Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors. Pathologe 30(4):292–301PubMedCrossRef

52.

Horn LC, Einenkel J, Handzel R, Höhn AK (2014) Morphology of secondary ovarian tumors and metastases. Pathologe 35(4):336–347PubMedCrossRef

53.

Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B, Richter CE, Braumann UD, Einenkel J (2006) Pattern of invasion is of prognostic value in surgically treated cervical cancer patients. Gynecol Oncol 103(3):906–911PubMedCrossRef

54.

Horn LC, Hentschel B, Bilek K, Richter CE, Einenkel J, Leo C (2006) Mixed small cell carcinomas of the uterine cervix: prognostic impact of focal neuroendocrine differentiation but not of Ki-67 labeling index. Ann Diagn Pathol 10(3):140–143PubMedCrossRef

55.

Horn LC, Hommel N, Roschlau U, Bilek K, Hentschel B, Einenkel J (2012) Peritumoral stromal remodeling, pattern of invasion and expression of c‑met/HGF in advanced squamous cell carcinoma of the cervix uteri, FIGO stages III and IV. Eur J Obstet Gynecol Reprod Biol 163(1):76–80PubMedCrossRef

56.

Howitt BE, Hanamornroongruang S, Lin DI, Conner JE, Schulte S, Horowitz N, Crum CP, Meserve EE (2015) Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am J Surg Pathol 39(3):287–293PubMedCrossRef

57.

Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer BL, Liles G, Karlan B, Köbel M, Lee CH, Soslow RA (2015) Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol 28(4):505–514PubMedCrossRef

58.

ICCR (2016) http://www.iccr-cancer.org/datasets/published-datasets/female-reproductive-organs/carcinoma-of-the-ovary-fallopian-tube-primary-peri. Zugegriffen: 29. März 2016

59.

Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP (2008) Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 53(2):127–138PubMedCrossRef

60.

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D (2014) POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecol Oncol 132(2):334–342PubMedCrossRef

61.

Kim SK, Cho NH (2014) HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis. Int J Clin Exp Pathol 7(7):4222–4230 (eCollection 2014)PubMedPubMedCentral

62.

Köbel M, Bell DA, Carcangiu ML, Oliva E, Prat J, Shih IM, Soslow R (2014) Undifferentiated carcinoma of the ovary. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reporductive tract. IARC, Lyon, S 40

63.

Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB, Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver BC (2010) Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 29(3):203–211PubMedCrossRef

64.

Kristensen GB, Abeler VM, Risberg B, Trop C, Bryne M (1999) Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma. Gynecol Oncol 74(2):245–251PubMedCrossRef

65.

Krivak TC, Seidman JD, McBroom JW, MacKoul PJ, Aye LM, Rose GS (2001) Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol 83(1):89–94PubMedCrossRef

66.

Kuhn E, Ayhan A, Shih Ie M, Seidman JD, Kurman RJ (2013) Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. Eur J Cancer 49(18):3839–3849PubMedCrossRef

67.

Kurman RJ, Shih M (2016) Seromucinous tumors of the ovary. What’s in a name? Int J Gynecol Pathol 35(1):78–81PubMedCrossRef

68.

Kurman RJ, Shih M (2016) The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol 186(4):733–747PubMedCrossRef

69.

Lange SS, Novetsky AP, Powell MA (2014) Recent advances in the treatment of sarcomas in gynecology. Discov Med 18(98):133–140PubMed

70.

Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM (2000) A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol 24(9):1201–1208PubMedCrossRef

71.

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15(8):852–861PubMedCrossRef

72.

Litta P, Saccardi C, Conte L, Codroma A, Angioni S, Mioni R (2013) Sertoli-Leydig cell tumors: current status of surgical management: literature review and proposal of treatment. Gynecol Endocrinol 29(5):412–417PubMedCrossRef

73.

Longacre TA, Bell DA, Malpica A, Prat J, Ronnett BM, Seidman JD, Vang R (2014) Mucinous tumours of the ovary. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reporductive tract. IARC, Lyon, S 25–28

74.

Lopez-Garcia MA, Palacios J (2010) Pathologic and molecular features of uterine carcinosarcomas. Semin Diagn Pathol 27(4):274–286PubMedCrossRef

75.

Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28(4):496–504PubMedCrossRef

76.

Malpica A, Deavers MT, Tornos C, Kurman RJ, Soslow R, Seidman JD, Munsell MF, Gaertner E, Frishberg D, Silva EG (2007) Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 31(8):1168–1174PubMedCrossRef

77.

Malpica A (2008) Grading of ovarian cancer: a histotype-specific approach. Int J Gynecol Pathol 27(2):175–181PubMed

78.

McCluggage WG (2004) WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol 23:97–99PubMedCrossRef

79.

McCluggage WG, Colgan T, Duggan M, Hacker NF, Mulvany N, Otis C, Wilkinson N, Zaino RJ, Hirschowitz L (2013) Data set for reporting of endometrial carcinomas: recommendations from the International Collaboration on Cancer Reporting (ICCR) between United Kingdom, United States, Canada, and Australasia. Int J Gynecol Pathol 32(1):45–65PubMedCrossRef

80.

McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H, Ledermann JA, Matias-Guiu X, Mikami Y, Stewart CJ, Vang R, Hirschowitz L (2015) Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 28(8):1101–1122PubMedCrossRef

81.

McCluggage WG, Young RH (2007) Ovarian sertoli-leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid sertoli-leydig cell tumors). Am J Surg Pathol 31(4):592–597 (Apr)PubMedCrossRef

82.

McCluggage WG (2011) Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 43(5):420–432PubMedCrossRef

83.

Meng B, Hoang LN, McIntyre JB, Duggan MA, Nelson GS, Lee CH, Köbel M (2014) POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol 134(1):15–19PubMedCrossRef

84.

Monk BJ, Dalton H, Farley JH, Chase DM, Benjamin I (2013) Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol Hematol 86(2):161–175PubMedCrossRef

85.

Nicoletto MO, Parenti A, Del Bianco P, Lombardi G, Pedrini L, Pizzi S, Carli P, Della Palma M, Pastorelli D, Corti L, Becagli L (2010) Vulvar cancer: prognostic factors. Anticancer Res 30(6):2311–2317PubMed

86.

Nik NN, Vang R, Shih Ie M, Kurman RJ (2014) Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol 9:27–45PubMedCrossRef

87.

Norris HJ, Zirkin HJ, Benson WL (1976) Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer 37(5):2359–2372PubMedCrossRef

88.

O’Connor DM, Norris HJ (1994) The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. Int J Gynecol Pathol 13(4):283–289PubMedCrossRef

89.

Ohishi Y, Imamura H, Aman M, Shida K, Kaku T, Kato K, Oda Y (2016) Is invasive micropapillary serous carcinoma a low-grade carcinoma? Int J Gynecol Pathol 35(1):56–65PubMedCrossRef

90.

Oliva E, Carcangiu ML, Carinelli SG, Ip P, Loening T, Longacre TA, Nucci MR, Prat J, Zaloudek CJ (2014) Mesenchymal tumors of the uterus. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reproductive tract. IARC, Lyon, S 135–147

91.

O’Neill CJ, McBride HA, Connolly LE, Deavers MT, Malpica A, McCluggage WG (2007) High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 50(6):773–779PubMedCrossRef

92.

Paquette C, Jeffus SK, Quick CM, Conaway MR, Stoler MH, Atkins KA (2015) Interobserver variability in the application of a proposed histologic subclassification of endocervical adenocarcinoma. Am J Surg Pathol 39(1):93–100PubMedCrossRef

93.

Pautier P, Nam EJ, Provencher DM, Hamilton AL, Mangili G, Siddiqui NA, Westermann AM, Reed NS, Harter P, Ray-Coquard I (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus. Int J Gynecol Cancer 24(9 Suppl 3):S73–7PubMedCrossRef

94.

Pocrnich CE, Ramalingam P, Euscher ED, Malpica A (2016) Neuroendocrine carcinoma of the Endometrium: A clinicopathologic study of 25 cases. Am J Surg Pathol : (Epub ahead of print)

95.

Poulsen HE, Taylor CW, Sobin LH (1975) Histological typing of female genital tract tumors. International Classification of Tumours. No 13. WHO, Gneneva

96.

Prahm KP, Karlsen MA, Høgdall E, Scheller NM, Lundvall L, Nedergaard L, Christensen IJ, Høgdall C (2015) The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. Gynecol Oncol 136(2):205–211PubMedCrossRef

97.

Prat J, Cao D, Carinelli SG, Nogales FF, Vang R, Zaloudek CJ (2014) Germ cell tumours of the ovary. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reporductive tract. IARC, Lyon, S 57–62

98.

Provenza C, Young RH, Prat J (2008) Anaplastic carcinoma in mucinous ovarian tumors: a clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules. Am J Surg Pathol 32(3):383–389PubMedCrossRef

99.

Rindi G, Arnold R, Bosman FT, Capella, Klimstra DS, Klöppel G, Komminoth P, Solcia E (2010) Nomenclature and classfification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (Hrsg) WHO classification of tumours of the gigestive system. IARC, Lyon, S 13–14

100.

Roma AA, Diaz De Vivar A, Park KJ, Alvarado-Cabrero I, Rasty G, Chanona-Vilchis JG, Mikami Y, Hong SR, Teramoto N, Ali-Fehmi R, Rutgers JK, Barbuto D, Silva EG (2015) Invasive endocervical adenocarcinoma: a new pattern-based classification system with important clinical significance. Am J Surg Pathol 39(5):667–672PubMedCrossRef

101.

Roma AA, Masand RP (2015) Different staining patterns of ovarian Brenner tumor and the associated mucinous tumor. Ann Diagn Pathol 19(1):29–32PubMedCrossRef

102.

Rouzbahman M, Clarke B (2013) Neuroendocrine tumors of the gynecologic tract: select topics. Semin Diagn Pathol 30(3):224–233PubMedCrossRef

103.

Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, Burke WM, Wright JD (2011) Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol 205(5):480.e1–480.e8CrossRef

104.

Scholten AN, Smit VT, Beerman H, van Putten WL, Creutzberg CL (2004) Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 100(4):764–772PubMedCrossRef

105.

Sehouli J, Woopen H, Pavel M, Richter R, Lauterbach LK, Taube E, Darb-Esfahani S, Fotopoulou C, Pietzner K (2016) Neuroendocrine neoplasms of the ovary: A retrospective study of the North Eastern German Society of Gynecologic Oncology (NOGGO). Anticancer Res 36(3):1003–1009PubMed

106.

Seidman JD, Bell DA, Crum CP, Gilks CB, Kurman RJ, Levine DA, Longacre TA, Pasini B, Riva C, Sherman ME, Shih IM, Singer G, Soslow R, Vang R (2014) Serous Ovarian Tumours. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO Classification of Tumours of Female Reporductive Tract. IARC, Lyon, S 17–24

107.

Seidman JD, Khedmati F (2008) Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors. Arch Pathol Lab Med 132(11):1753–1760 (Nov)PubMed

108.

Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Villella J, Herzog T, Abu Shahin F, SGO Clinical Practice Endometrial Cancer Working Group, Society of Gynecologic Oncology Clinical Practice Committee (2014) Endometrial cancer: a review and current management strategies: part. Gynecol Oncol 134(2):385–392PubMedCrossRef

109.

Shah CA, Goff BA, Lowe K, Peters WA 3rd, Li CI (2009) Factors affecting risk of mortality in women with vaginal cancer. Obstet Gynecol 113(5):1038–1045PubMedPubMedCentralCrossRef

110.

Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ (2002) Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol 26(12):1529–1541PubMedCrossRef

111.

Shaw PA (2011) Hereditary carcinomas of the ovary, fallopian tube, and peritoneum. Surg Pathol Clin 4(1):461–478PubMedCrossRef

112.

Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG (1998) Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82(5):893–901PubMedCrossRef

113.

Shu CA, Zhou Q, Jotwani AR, Iasonos A, Leitao MM Jr, Konner JA, Aghajanian CA (2015) Ovarian clear cell carcinoma, outcomes by stage: the MSK experience. Gynecol Oncol 139(2):236–241 (Nov)PubMedCrossRef

114.

Silva EG, Deavers MT, Bodurka DC, Malpica A (2006) Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol 25(1):52–58PubMedCrossRef

115.

Silverberg SG (2000) Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19(1):7–15PubMedCrossRef

116.

Singh N, Arif S (2004) Histopathologic parameters of prognosis in cervical cancer – a review. Int J Gynecol Cancer 14(5):741–750PubMedCrossRef

117.

Singh N, Gilks CB, Wilkinson N, McCluggage WG (2014) Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology 65(2):149–154PubMedCrossRef

118.

Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, Kauff ND, Levine DA (2012) Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 25(4):625–636PubMedCrossRef

119.

Steiner E, Einenkel J, Schmidt D, Horn LC (2012) Prädiktive und prognostische Marker beim Endometriumkarzinom. Onkologe 18:853–865CrossRef

120.

Stock RJ, Zaino R, Bundy BN, Askin FB, Woodward J, Fetter B, Paulson JA, DiSaia PJ, Stehman FB (1994) Evaluation and comparison of histopathologic grading systems of epithelial carcinoma of the uterine cervix: Gynecologic Oncology Group studies. Int J Gynecol Cancer 13(2):99–108CrossRef

121.

Stoler M, Bergeron C, Colgan TJ, Ferenczy AS, Herrington CS, Kim KR, Loening T, Schneider A, Sherman ME, Wilbur DC, Wright T (2014) Squamous cell tumours and precursors of the uterine cervix. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reporductive tract. IARC, Lyon, S 172–182

122.

Stolnicu S, Molnar C, Barsan I, Boros M, Nogales FF, Soslow RA (2016) The impact on survival of an extensive sex cord-like component in Mullerian adenosarcomas: a study comprising 6 cases. Int J Gynecol Pathol 35(2):147–152PubMedCrossRef

123.

Sung CO, Song IH, Sohn I (2014) A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19. Gynecol Oncol 132(2):343–350PubMedCrossRef

124.

Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA (2010) Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol 23(6):781–789PubMedCrossRef

125.

Taylor J, McCluggage WG (2015) Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm. Am J Surg Pathol 39(7):983–992PubMedCrossRef

126.

Taylor RR, Zeller J, Lieberman RW, O’Connor DM (1999) An analysis of two versus three grades for endometrial carcinoma. Gynecol Oncol 74(1):3–6PubMedCrossRef

127.

Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Gertig D, DeFazio A, Bowtell DD, Australian Ovarian Cancer Study Group (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14(16):5198–5208PubMedCrossRef

128.

Watkin W, Silva EG, Gershenson DM (1992) Mucinous carcinoma of the ovary. Pathologic prognostic factors. Cancer 69(1):208–212PubMedCrossRef

129.

Wells M, Oliva E, Palacios J, Prat J (2014) Mixed epithelial and mesenchymal tumors of the uterine corpus. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reporductive tract. IARC, Lyon, S 148–151

130.

Wentz WB, Reagan JW (1959) Survival in cervical cancer with respect to cell type. Cancer 12:384–388PubMedCrossRef

131.

Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ (2012) Contemporary management of endometrial cancer. Lancet 379(9823):1352–1360PubMedCrossRef

132.

Yadav V, Chen SH, Yue YG, Buchanan S, Beckmann RP, Peng SB (2015) Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. Pharmacol Ther 149:139–149PubMedCrossRef

133.

Yamamoto S, Kasajima A, Takano M, Yaegashi N, Fujiwara H, Kuzuya K, Kigawa J, Tsuda H, Kurachi H, Kikuchi Y, Sugiyama T, Tsuda H, Moriya T (2011) Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group. Int J Gynecol Pathol 30(2):129–138PubMedCrossRef

134.

Yanai-Inbar I, Scully RE (1987) Relation of ovarian dermoid cysts and immature teratomas: an analysis of 350 cases of immature teratoma and 10 cases of dermoid cyst with microscopic foci of immature tissue. Int J Gynecol Pathol 6(3):203–212PubMedCrossRef

135.

Young RH, Scully RE (1985) Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 9(8):543–569PubMedCrossRef

136.

Young RH (1993) Sertoli-Leydig cell tumors of the ovary: review with emphasis on historical aspects and unusual variants. Int J Gynecol Pathol 12(2):141–147PubMedCrossRef

137.

Zaino R, Carinelli SG, Ellenson LH, Rng C, Katabuchi H, Konishi I, Lax S, Matias-Giu X, Mutter GL, Peters WA, Sherman ME, Shih IM, Soslow R, Stewart CJR (2014) Epitehlail tumors and precursosr of the endometrium. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reporductive tract. IARC, Lyon, S 125–135

138.

Zaino RJ, Kurman RJ, Diana KL, Morrow CP (1995) The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 75(1):81–86PubMedCrossRef

139.

Zaloudek C, Norris HJ (1984) Sertoli-Leydig tumors of the ovary. A clinicopathologic study of 64 intermediate and poorly differentiated neoplasms. Am J Surg Pathol 8(6):405–418PubMedCrossRef

140.

Zeppernick F, Meinhold-Heerlein I (2014) The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet 290(5):839–842 (Nov)PubMedCrossRef

Titel: Grading gynäkologischer Tumoren
Aktuelle Aspekte
verfasst von: Prof. Dr. L.-C. Horn
D. Mayr
C. E. Brambs
J. Einenkel
I. Sändig
K. Schierle
Publikationsdatum: 05.07.2016
Verlag: Springer Berlin Heidelberg
Schlagwörter: Gynäkologische Tumoren
Sarkome
Ovarialkarzinom
Endometriumkarzinom
Neuroendokrine Tumoren
Endometriumkarzinom
Ovarialkarzinom
Erschienen in: Die Pathologie / Ausgabe 4/2016
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI: https://doi.org/10.1007/s00292-016-0183-7

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Grading gynäkologischer Tumoren

Aktuelle Aspekte

Zusammenfassung

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

WHO-ISUP-Graduierungssystem für Nierenkarzinome

Histologisches Grading beim Mammakarzinom

Grading von Prostatakarzinomen

Grading neuroendokriner Tumoren

Klinisch-epidemiologische Krebsregistrierung in Deutschland

Mitteilungen der Deutschen Gesellschaft für Pathologie

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien